Search

Your search keyword '"Nauck, Michael A."' showing total 1,261 results
Start Over Author "Nauck, Michael A."
1,261 results on '"Nauck, Michael A."'

2. Therapie des Typ-2-Diabetes

Author

Landgraf, Rüdiger, Aberle, Jens, Birkenfeld, Andreas L., Gallwitz, Baptist, Kellerer, Monika, Klein, Harald H., Müller-Wieland, Dirk, Nauck, Michael A., Wiesner, Tobias, and Siegel, Erhard

Published
2024
Full Text
View/download PDF

7. CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

Author

Schnell, Oliver, Battelino, Tadej, Bergenstal, Richard, Birkenfeld, Andreas L., Ceriello, Antonio, Cheng, Alice, Davies, Melanie, Edelman, Steve, Forst, Thomas, Giorgino, Francesco, Green, Jennifer, Groop, Per-Henrik, Hadjadj, Samy, J.L.Heerspink, Hiddo, Hompesch, Marcus, Izthak, Baruch, Ji, Linong, Kanumilli, Naresh, Mankovsky, Boris, Mathieu, Chantal, Miszon, Martin, Mustafa, Reem, Nauck, Michael, Pecoits-Filho, Roberto, Pettus, Jeremy, Ranta, Kari, Rodbard, Helena W., Rossing, Peter, Ryden, Lars, Schumm-Draeger, Petra-Maria, Solomon, Scott D., Škrha, Jan, Topsever, Pinar, Vilsbøll, Tina, Wilding, John, and Standl, Eberhard

Published
2023
Full Text
View/download PDF

8. Therapie des Typ-2-Diabetes

Author

Landgraf, Rüdiger, Aberle, Jens, Birkenfeld, Andreas L., Gallwitz, Baptist, Kellerer, Monika, Klein, Harald H., Müller-Wieland, Dirk, Nauck, Michael A., Wiesner, Tobias, and Siegel, Erhard

Published
2023
Full Text
View/download PDF

10. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics

Author

Nicholls, Stephen J., Bhatt, Deepak L, Buse, John B, Prato, Stefano Del, Kahn, Steven E, Lincoff, A Michael, McGuire, Darren K, Nauck, Michael A, Nissen, Steven E, Sattar, Naveed, Zinman, Bernard, Zoungas, Sophia, Basile, Jan, Bartee, Amy, Miller, Debra, Nishiyama, Hiroshi, Pavo, Imre, Weerakkody, Govinda, Wiese, Russell J, and D'Alessio, David

Published
2024
Full Text
View/download PDF

12. Therapie des Typ-2-Diabetes

Author

Landgraf, Rüdiger, Aberle, Jens, Birkenfeld, Andreas L., Gallwitz, Baptist, Kellerer, Monika, Klein, Harald H., Müller-Wieland, Dirk, Nauck, Michael A., Wiesner, Tobias, and Siegel, Erhard

Published
2022
Full Text
View/download PDF

13. Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes

Author

Schnell, Oliver, Battelino, Tadej, Bergenstal, Richard, Blüher, Matthias, Böhm, Michael, Brosius, Frank, Carr, Richard D., Ceriello, Antonio, Forst, Thomas, Giorgino, Francesco, Guerci, Bruno, Heerspink, Hiddo J. L., Itzhak, Baruch, Ji, Linong, Kosiborod, Mikhail, Lalić, Nebojša, Lehrke, Michael, Marx, Nikolaus, Nauck, Michael, Rodbard, Helena W., Rosano, Giuseppe M. C., Rossing, Peter, Rydén, Lars, Santilli, Francesca, Schumm-Draeger, Petra-Maria, Vandvik, Per Olav, Vilsbøll, Tina, Wanner, Christoph, Wysham, Carol, and Standl, Eberhard

Published
2022
Full Text
View/download PDF

17. Randomised comparison of intravenous and subcutaneous routes of glucagon‐like peptide‐1 administration for lowering plasma glucose in hyperglycaemic subjects with type 2 diabetes.

Author

Quast, Daniel R., Lancaster, Dara, Xie, Cong, Bound, Michelle J., Grivell, Jacqueline, Jones, Karen L., Horowitz, Michael, Meier, Juris J., Wu, Tongzhi, Rayner, Christopher K., and Nauck, Michael A.

Subjects
PATHOLOGICAL physiology, BLOOD sugar, TYPE 2 diabetes, SECRETION, GLUCAGON, INSULIN
Abstract

Aim: To perform a direct, double‐blind, randomised, crossover comparison of subcutaneous and intravenous glucagon‐like peptide‐1 (GLP‐1) in hyperglycaemic subjects with type 2 diabetes naïve to GLP‐1‐based therapy. Materials and Methods: Ten fasted, hyperglycaemic subjects (1 female, age 63 ± 10 years [mean ± SD], glycated haemoglobin 73.5 ± 22.0 mmol/mol [8.9% ± 2.0%], both mean ± SD) received subcutaneous GLP‐1 and intravenous saline, or intravenous GLP‐1 and subcutaneous saline. Infusion rates were doubled every 120 min (1.2, 2.4, 4.8 and 9.6 pmol·kg−1·min−1 for subcutaneous, and 0.3, 0.6, 1.2 and 2.4 pmol·kg−1·min−1 for intravenous). Plasma glucose, total and intact GLP‐1, insulin, C‐peptide, glucagon and gastrointestinal symptoms were evaluated over 8 h. The results are presented as mean ± SEM. Results: Plasma glucose decreased more with intravenous (by ~8.0 mmol/L [144 mg/dL]) than subcutaneous GLP‐1 (by ~5.6 mmol/L [100 mg/dL]; p < 0.001). Plasma GLP‐1 increased dose‐dependently, but more with intravenous than subcutaneous for both total (∆max 154.2 ± 3.9 pmol/L vs. 85.1 ± 3.8 pmol/L; p < 0.001), and intact GLP‐1 (∆max 44.2 ± 2.2 pmol/L vs. 12.8 ± 2.2 pmol/L; p < 0.001). Total and intact GLP‐1 clearance was higher for subcutaneous than intravenous GLP‐1 (p < 0.001 and p = 0.002, respectively). The increase in insulin secretion was greater, and glucagon was suppressed more with intravenous GLP‐1 (p < 0.05 each). Gastrointestinal symptoms did not differ (p > 0.05 each). Conclusions: Subcutaneous GLP‐1 administration is much less efficient than intravenous GLP‐1 in lowering fasting plasma glucose, with less stimulation of insulin and suppression of glucagon, and much less bioavailability, even at fourfold higher infusion rates. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Therapy of Type 2 Diabetes

Author

Landgraf, Rüdiger, additional, Aberle, Jens, additional, Birkenfeld, Andreas L., additional, Gallwitz, Baptist, additional, Kellerer, Monika, additional, Klein, Harald H., additional, Müller-Wieland, Dirk, additional, Nauck, Michael A., additional, Wiesner, Tobias, additional, and Siegel, Erhard, additional

Published
2024
Full Text
View/download PDF

24. Therapie des Typ-2-Diabetes

Author

Landgraf, Rüdiger, Aberle, Jens, Birkenfeld, Andreas L., Gallwitz, Baptist, Kellerer, Monika, Klein, Harald H., Müller-Wieland, Dirk, Nauck, Michael A., Reuter, Hans-Martin, and Siegel, Erhard

Published
2021
Full Text
View/download PDF

27. Treatment of type 2 diabetes

Author

Landgraf, Rüdiger, primary, Aberle, Jens, additional, Birkenfeld, Andreas L., additional, Gallwitz, Baptist, additional, Kellerer, Monika, additional, Klein, Harald H., additional, Müller-Wieland, Dirk, additional, Nauck, Michael A., additional, Wiesner, Tobias, additional, and Siegel, Erhard, additional

Published
2024
Full Text
View/download PDF

31. Therapie des Typ-2-Diabetes

Author

Landgraf, Rüdiger, Aberle, Jens, Birkenfeld, Andreas L., Gallwitz, Baptist, Kellerer, Monika, Klein, Harald, Müller-Wieland, Dirk, Nauck, Michael A., Reuter, Hans-Martin, and Siegel, Erhard

Published
2020
Full Text
View/download PDF

36. Therapie des Typ-2-Diabetes

Author

Landgraf, Rüdiger, additional, Aberle, Jens, additional, Birkenfeld, Andreas L., additional, Gallwitz, Baptist, additional, Kellerer, Monika, additional, Klein, Harald H., additional, Müller-Wieland, Dirk, additional, Nauck, Michael A., additional, Wiesner, Tobias, additional, and Siegel, Erhard, additional

Published
2023
Full Text
View/download PDF

39. Getting the measure of the pressure: Optimal assessment of the effects of glucagon‐like peptide‐1 receptor agonists on blood pressure.

Author

Jones, Karen L., Marathe, Chinmay S., Wu, Tongzhi, Rayner, Christopher K., Nauck, Michael, and Horowitz, Michael

Subjects
GLUCAGON-like peptide-1 receptor, GASTRIC emptying, BLOOD pressure, GLUCAGON-like peptide-1 agonists, HEALTH facilities, DIASTOLIC blood pressure
Abstract

The article discusses the effects of glucagon-like peptide-1 (GLP-1) receptor agonists on blood pressure. GLP-1 receptor agonists have been shown to have cardiovascular and renal protective effects, independent of their glucose-lowering properties. While these drugs have been found to reduce systolic blood pressure in hypertensive individuals, they have little effect on diastolic blood pressure or normotensive individuals. The article also highlights the importance of accurately measuring blood pressure, including postprandial blood pressure, and suggests that further research is needed to optimize the assessment of the effects of GLP-1 receptor agonists on blood pressure. [Extracted from the article]

Published
2024
Full Text
View/download PDF

40. Therapie des Typ-2-Diabetes

Author

Landgraf, Rüdiger, Kellerer, Monika, Aberle, Jens, Fach, Eva-Maria, Gallwitz, Baptist, Hamann, Andreas, Joost, Hans-Georg, Klein, Harald, Müller-Wieland, Dirk, Nauck, Michael A., Reuter, Hans-Martin, Schreiber, Stephan, and Siegel, Erhard

Published
2019
Full Text
View/download PDF

47. A Methodological Framework for Meta-analysis and Clinical Interpretation of Subgroup Data: The Case of Major Adverse Cardiovascular Events With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes.

Author

Karagiannis, Thomas, Tsapas, Apostolos, Bekiari, Eleni, Toulis, Konstantinos A., and Nauck, Michael A.

Subjects
MAJOR adverse cardiovascular events, TYPE 2 diabetes, SODIUM-glucose cotransporter 2 inhibitors, GLUCAGON-like peptide-1 agonists, GLUCAGON-like peptide 1
Abstract

We present a methodological framework for conducting and interpreting subgroup meta-analyses. Methodological steps comprised evaluation of clinical heterogeneity regarding the definition of subpopulations, credibility assessment of subgroup meta-analysis, and translation of relative into absolute treatment effects. We used subgroup data from type 2 diabetes cardiovascular outcomes trials (CVOTs) with glucagon-like peptide 1 (GLP-1) receptor agonists and sodium–glucose cotransporter 2 (SGLT2) inhibitors for patients with established cardiovascular disease and those at high cardiovascular risk without manifest cardiovascular disease. First, we evaluated the variability in definitions of the subpopulations across CVOTs using major adverse cardiovascular events (MACE) incidence in the placebo arm as a proxy for baseline cardiovascular risk. As baseline risk did not differ considerably across CVOTs, we conducted subgroup meta-analyses of hazard ratios (HRs) for MACE and assessed the credibility of a potential effect modification. Results suggested using the same overall relative effect for each of the two subpopulations (HR 0.85, 95% CI 0.80–0.90, for GLP-1 receptor agonists and HR 0.91, 95% CI 0.85–0.97, for SGLT2 inhibitors). Finally, we calculated 5-year absolute treatment effects (number of fewer patients with event per 1,000 patients). Treatment with GLP-1 receptor agonists resulted in 30 fewer patients with event in the subpopulation with established cardiovascular disease and 14 fewer patients with event in patients without manifest cardiovascular disease. For SGLT2 inhibitors, the respective absolute effects were 18 and 8 fewer patients with event per 1,000 patients. This framework can be applied to subgroup meta-analyses regardless of outcomes or modification variables. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

50. Treatment of type 2 diabetes

Author

Landgraf, Rüdiger, primary, Aberle, Jens, additional, Birkenfeld, Andreas L., additional, Gallwitz, Baptist, additional, Kellerer, Monika, additional, Klein, Harald H., additional, Müller-Wieland, Dirk, additional, Nauck, Michael A., additional, Wiesner, Tobias, additional, and Siegel, Erhard, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results